Last reviewed · How we verify
PHENCYCLIDINE
PHENCYCLIDINE is a phencyclidine drug. It is currently in Phase 2 development.
Phencyclidine blocks the action of glutamate at the NMDA receptor, disrupting normal neural communication.
Phencyclidine (PCP) is a small molecule drug that targets the glutamate NMDA receptor. It is a non-competitive antagonist, meaning it blocks the receptor's action without binding to the same site as the endogenous ligand. PCP is not FDA-approved for any indications and is primarily known for its dissociative and hallucinogenic effects. Its commercial status is unknown, and it is not widely available as a generic medication. Key safety considerations include its potential for abuse and dependence, as well as its ability to cause psychosis and other severe psychiatric symptoms.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PHENCYCLIDINE |
|---|---|
| Drug class | phencyclidine |
| Target | Lysosomal Pro-X carboxypeptidase, Sigma non-opioid intracellular receptor 1, Glutamate NMDA receptor; GRIN1/GRIN2A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is a city with many streets (neurons) and intersections (synapses). Glutamate is like a traffic cop that helps guide the flow of information between streets. Phencyclidine is like a roadblock that prevents the traffic cop from doing its job, causing confusion and disrupting the normal flow of information.
Approved indications
Common side effects
- Drug abuse
- Toxicity to various agents
Key clinical trials
- Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHENCYCLIDINE CI brief — competitive landscape report
- PHENCYCLIDINE updates RSS · CI watch RSS
Frequently asked questions about PHENCYCLIDINE
What is PHENCYCLIDINE?
How does PHENCYCLIDINE work?
What drug class is PHENCYCLIDINE in?
What development phase is PHENCYCLIDINE in?
What are the side effects of PHENCYCLIDINE?
What does PHENCYCLIDINE target?
Related
- Drug class: All phencyclidine drugs
- Target: All drugs targeting Lysosomal Pro-X carboxypeptidase, Sigma non-opioid intracellular receptor 1, Glutamate NMDA receptor; GRIN1/GRIN2A
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing